661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Subjects

Subjects :

Oncology
medicine.medical_specialty
5 year follow up
Sunitinib
business.industry
First line
Checkmate
Ipilimumab
Hematology
medicine.disease
Conditional survival
Renal cell carcinoma
Internal medicine
medicine
Nivolumab
business
medicine.drug

Details

ISSN :

09237534

Volume :

32

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........80b15ae257a668092655f671a2df513f

Full Text :

https://doi.org/10.1016/j.annonc.2021.08.057